B E Loveland

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. ncbi A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization
    Mandy J Ludford-Menting
    Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    J Biol Chem 277:4477-84. 2002
  2. ncbi Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons
    Bruce E Loveland
    The Austin Research Institute, Heidelberg, Victoria, Australia
    Xenotransplantation 11:171-83. 2004
  3. pmc Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
    Vasso Apostolopoulos
    Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Victoria, Australia
    Breast Cancer Res 8:R27. 2006
  4. ncbi Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
    Bruce E Loveland
    Austin Research Institute, and Medical Oncology Unit, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia
    Clin Cancer Res 12:869-77. 2006
  5. ncbi Genetic engineering for xenotransplantation
    M S Sandrin
    Molecular Immunogenetics Laboratory, The Austin Research Institute, Heidelberg, Victoria, Australia
    J Card Surg 16:448-57. 2001
  6. doi Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors
    K L Jones
    Department of Immunology, Monash University, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia
    J Viral Hepat 15:761-72. 2008
  7. ncbi Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses
    Vasso Apostolopoulos
    The Austin Research Institute, Kronheimer Building, Studley Road, Heidelberg, VIC 3084, Australia
    Vaccine 24:3191-202. 2006
  8. ncbi CD46 protects pig islets from antibody but not cell-mediated destruction in the mouse
    Ian F C McKenzie
    The Austin Research Institute, Heidelberg, Victoria, Australia
    Xenotransplantation 10:615-21. 2003
  9. ncbi Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis
    Blessing Crimeen-Irwin
    Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    J Biol Chem 278:46927-37. 2003
  10. ncbi Aspects of cancer immunotherapy
    Ian F C McKenzie
    The Austin Research Institute, Heidelberg, Victoria, Australia
    Immunol Cell Biol 81:79-85. 2003

Collaborators

Detail Information

Publications13

  1. ncbi A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization
    Mandy J Ludford-Menting
    Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    J Biol Chem 277:4477-84. 2002
    ..These data also indicate that, in addition to the known role for DLG4 in neuronal cells, DLG4 may be important for polarization in epithelial cells...
  2. ncbi Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons
    Bruce E Loveland
    The Austin Research Institute, Heidelberg, Victoria, Australia
    Xenotransplantation 11:171-83. 2004
    ....
  3. pmc Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
    Vasso Apostolopoulos
    Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Victoria, Australia
    Breast Cancer Res 8:R27. 2006
    ..To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1...
  4. ncbi Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
    Bruce E Loveland
    Austin Research Institute, and Medical Oncology Unit, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia
    Clin Cancer Res 12:869-77. 2006
    ..Tumor antigen-loaded dendritic cells show promise for cancer immunotherapy. This phase I study evaluated immunization with autologous dendritic cells pulsed with mannan-MUC1 fusion protein (MFP) to treat patients with advanced malignancy...
  5. ncbi Genetic engineering for xenotransplantation
    M S Sandrin
    Molecular Immunogenetics Laboratory, The Austin Research Institute, Heidelberg, Victoria, Australia
    J Card Surg 16:448-57. 2001
    ..There will undoubtedly be other molecular incompatibilities that need addressing. Xenotransplantation, however, offers hope as a therapeutic solution and provides much information about homeostatic mechanisms...
  6. doi Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors
    K L Jones
    Department of Immunology, Monash University, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia
    J Viral Hepat 15:761-72. 2008
    ..These findings reveal conditions for generating mature antigen-loaded DC suitable for targeted immunotherapy...
  7. ncbi Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses
    Vasso Apostolopoulos
    The Austin Research Institute, Kronheimer Building, Studley Road, Heidelberg, VIC 3084, Australia
    Vaccine 24:3191-202. 2006
    ..Immunized C57BL/6 mice were protected against the growth of a MUC1(+) tumor cell line...
  8. ncbi CD46 protects pig islets from antibody but not cell-mediated destruction in the mouse
    Ian F C McKenzie
    The Austin Research Institute, Heidelberg, Victoria, Australia
    Xenotransplantation 10:615-21. 2003
    ....
  9. ncbi Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis
    Blessing Crimeen-Irwin
    Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    J Biol Chem 278:46927-37. 2003
    ..This has important implications for CD46 signaling, antigen presentation, CD46 down-regulation, and engulfment of pathogens...
  10. ncbi Aspects of cancer immunotherapy
    Ian F C McKenzie
    The Austin Research Institute, Heidelberg, Victoria, Australia
    Immunol Cell Biol 81:79-85. 2003
    ....
  11. ncbi Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46)
    Eleni Giannakis
    Department of Microbiology and Infectious Diseases, Flinders Medical Center, Flinders University, Bedford Park, Adelaide, SA, Australia
    J Immunol 168:4585-92. 2002
    ....
  12. ncbi Dendritic cell vaccination
    Owen Proudfoot
    Bio Organic and Medicinal Chemistry Laboratory, Burnet Institute at Austin, Studley Rd, Heidelberg, 3084, Victoria, Australia
    Expert Rev Vaccines 6:617-33. 2007
    ..Finally, the methodology used to generate human DCs and some recent clinical trials in several cancers are reviewed...
  13. ncbi Cancer exploiting complement: a clue or an exception?
    Bruce E Loveland
    Nat Immunol 9:1205-6. 2008